Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 5—May 2023
Research Letter

COVID-19 Vaccine Uptake by Infection Status in New South Wales, Australia

Heather F. GiddingComments to Author , Sandrine Stepien, Jiahui Qian, Kristine K. Macartney, and Bette Liu
Author affiliations: University of Sydney Northern Clinical School, St. Leonards, New South Wales, Australia (H.F. Gidding); National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia (H.F. Gidding, S. Stepien, J. Qian, K.K. Macartney, B. Liu); University of New South Wales School of Population Health, Kensington, New South Wales, Australia (H.F. Gidding, J. Qian, B. Liu); University of Sydney Faculty of Medicine and Health, Camperdown, New South Wales, Australia (H.F. Gidding, K.K. Macartney)

Main Article

Table

Age and dose specific cohorts and their distribution in study of COVID-19 vaccine uptake, by infection status on May 29, 2022, Greater Sydney Metropolitan and Hunter New England areas, New South Wales, Australia

Age group, y Current dose* Next dose* Recommended time between current and next dose, d Total cohort Uninfected, no. (%) Infected, no. (%)
Before current dose Before next dose due After next dose due
5–11
 Dose 1
 Dose 2
 63†
 285,638
 210,004 (73.5)
 18,611 (6.5)
 49,888 (17.5)
 7,135 (2.5)
12–15
 Dose 1
 Dose 2
 28‡
 241,490
 236,900 (98.1)
 1,962 (0.8)
 889 (0.4)
 1,739 (0.7)
16–39
 Dose 2
 Dose 3
 91§
 1864,335
 1,413,329 (75.8)
 15,345 (0.8)
 68,578 (3.7)
 367,083 (19.7)
40–64
 Dose 2
 Dose 3
 91§
 1,727,123
 1,503,582 (87.1)
 7,968 (0.5)
 21,456 (1.2)
 194,117 (11.2)
≥65 Dose 2 Dose 3 91§ 885,564 841,931 (95.1) 1,689 (0.2) 5,544 (0.6) 36,400 (4.1)
Dose 3 Dose 4 91§ 779,649 679,155 (87.1) 24,042 (3.1) 42,464 (5.4) 33,988 (4.4)

*Cohorts were assembled based on the current dose under consideration and retrospectively followed up to determine if they received the next dose. †Children 5–11 y of age: recommended interval between doses 1 and 2 was 8 wk so dose 2 due date was set at 9 wk (63 d). ‡Most children 12–15 y of age: recommended interval between doses 1 and 2 was 3 wk so the dose 2 due date was set at 4 wk (28 d). §For persons ≥16 y of age: recommended interval between doses 2 and 3 changed from November 2021 to January 2022 to 3 mo so the dose 3 due date was set at 91 d; 3 mo was also the most recently recommended interval between doses 3 and 4.

Main Article

Page created: March 15, 2023
Page updated: April 19, 2023
Page reviewed: April 19, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external